IDEXX LABORATORIES INC /DE Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
IDEXX LABORATORIES INC /DE (IDXX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2024-10-31
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-12-31 was $0.00.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-09-30 was $99.00K.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $99.00K, a 98.61% decline from fiscal 2022.
- IDEXX LABORATORIES INC /DE fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $7.11M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $99.00K derived: sum of 2 quarters · filed 2024-10-31 | $99.00K 10-K · filed 2024-02-22 | |
| 2023-09-30 | $99.00K 10-Q · filed 2024-10-31 | $99.00K 10-Q · filed 2024-10-31 | ||
| 2022-12-31 | $7.11M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |